Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene-therapy
company, this morning announced that it will be presenting at the upcoming
Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf
Astoria Chicago on May 31, 2019. Per the update, Genprex President and COO
Julien Pham, MD, MPH, will lead the company’s presentation at 11:10 a.m. CT in
the Waldorf Astoria Chicago’s Sinclair Ballroom. Pham will also be available
for one-on-one meetings at the event.
To view the full press release, visit http://ibn.fm/2Ofl7
About Genprex Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex immunogene therapy for non-small cell lung cancer
(NSCLC). Genprex’s platform technologies are designed to administer cancer
fighting genes by encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken up by tumor
cells where they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts cell
signaling pathways that cause replication and proliferation of cancer cells,
re-establishes pathways for apoptosis, or programmed cell death, in cancer
cells, and modulates the immune response against cancer cells. Oncoprex has
also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment